Recent Updates
Recently added Catalysts

Acasunlimab

Phase 3

PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | Small molecule | Oncology |Genmab A/S|Last Updated: Mar 11, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment191
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06635824Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)PHASE3 ACTIVE NOT_RECRUITING 191 — — Nov 1, 2024Sep 1, 2028Mar 11, 2026 - —
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
AcasunlimabDRUGIV infusion
PembrolizumabDRUGIV infusion
DocetaxelDRUGIV infusion
Unlock Study Design Details
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT06635824studyFirstPostDate: changed